DOI: 10.1515/mr-2021-0010
Gene editing therapy ready for cardiovascular diseases:opportunities,challenges,and perspectives
Jun Zhou1
Zhuoying Ren1
Jie Xu2
Jifeng Zhang2
Y.Eugene Chen3
1.Center for Advanced Models for Translational Sciences and Therapeutics,University of Michigan Medical Center,Ann Arbor 48109,MI,USA;Department of Pharmacology,University of Michigan Medical Center,Ann Arbor 48109,MI,USA2.Center for Advanced Models for Translational Sciences and Therapeutics,University of Michigan Medical Center,Ann Arbor 48109,MI,USA3.Center for Advanced Models for Translational Sciences and Therapeutics,University of Michigan Medical Center,Ann Arbor 48109,MI,USA;Department of Pharmacology,University of Michigan Medical Center,Ann Arbor,MI 48109,USA
摘要：Gene editing nucleases(GENs),represented by CRISPR/Cas9,have become major tools in biomedical research and offer potential cures for many human diseases.Gene editing therapy(GETx)studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9(PCSK9),apolipoprotein C3(APOC3),angiopoietin Like 3(ANGPTL3)and inducible degrader of the low-density lipoprotein receptor(IDOL)have demonstrated the benefits and advantages of GETx in managing atherosclerosis.Here we present our views on this brand new therapeutic option for cardiovascular diseases(CVD).
机标关键词：genecardiovascularchallengesdiseaseseditingopportunitiesperspectivesready
论文发表日期：2021-02-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：4( 6-9 )
英文信息